The quest for the holy grail: new antitubercular chemical entities, targets and strategies.

Drug discovery today, Volume: 25, Issue: 4
April 13, 2020
Stanislav Huszár S, Kelly Chibale K, Vinayak Singh V

Tuberculosis (TB) remains the leading cause of death from an infectious disease worldwide. TB therapy is complicated by the protracted treatment regimens, development of resistance coupled with toxicity and insufficient sterilizing capacity of current drugs. Although considerable progress has been made on establishing a TB drug pipeline, the high attrition rate reinforces the need to continually replenish the pipeline with high-quality leads that act through inhibition of novel targets. In this review, we highlight some of the key advances that have assisted TB drug discovery with novel chemical matter, targets and strategies – to fuel the TB drug pipeline.

Courtesy of the U.S. National Library of Medicine